Defibrillator leads

OmniaSecure™ defibrillation lead

OmniaSecure™ defibrillation lead 3930.OmniaSecure™ defibrillation lead 3930.
No Image Available

Defibrillator leads

OmniaSecure™ defibrillation lead

The OmniaSecure™ lead is 4.7 French in diameter and catheter-delivered to enable targeted lead placement in the right ventricle.

 

Ordering information
Contact a representative
Indications, Safety, and Warnings

Description

The world’s smallest defibrillation lead. Built for high reliability.

The OmniaSecure™ MRI SureScan™ defibrillation lead is designed for pacing, sensing, cardioversion, and defibrillation therapies. The lead is an integrated bipolar lead, single coil, with DF4 connection and has been evaluated for safety and efficacy in the Lead EvaluAtion for Defibrillation and Reliability (LEADR) Global Pivotal Trial (NCT04863664).

Features

This is an image of the OmniaSecure™ defibrillation lead.

The world’s smallest defibrillation lead

  • 4.7 Fr, 64% smaller than Sprint Quattro™ defibrillator lead1
  • May reduce potential lead-related complications, such as vascular occlusion or tricuspid valve complications2–4
This is a close-up view of the OmniaSecure™ defibrillation lead stress test to ensure durability at implantation.

Built for high reliability

Durable, lumenless construction

  • Built on the proven SelectSecure™ 3830 pacing lead platform5,6
  • 98.2% projected 10-year fracture-free rate, based on comprehensive, robust benchtop testing7

Reliable therapy delivery

  • 97.5% defibrillation efficacy at implant5
  • Stable electricals (sensing, pacing, impedance) through two years5
This is an illustration showing how the OmniaSecure™ defibrillation lead is implanted into the heart.

Catheter delivery enables targeted lead placement

  • 97.9% implant success rate with 99.5% of leads placed in desired right ventricular location5
  • Full portfolio of catheter shapes to enable targeted placement within the right ventricle

Clinical evidence

OmniaSecure™ LEADR Global Pivotal Trial

The OmniaSecure™ lead has demonstrated high defibrillation success, low complications, and reliable therapy delivery in the LEADR Global Pivotal Trial.

97.5% defibrillation efficacy at implant

Primary objective passed, exceeding performance goal, and in line with industry reports5

96.9% freedom from OmniaSecure™ lead-related major complications at two years

Primary safety objective met, exceeding performance goal, and in line with industry reports8

Reliable performance with zero lead fractures and stable electricals
  • Zero fractures through all follow-up (17.8 ± 6.0 months) and stable pacing, sensing, and impedance
  • 97.9% implant success rate with 99.5% of leads placed in desired right ventricular location8
View the primary manuscript (open in new window)

Cardiac Lead Reliability Model — OmniaSecure™ 10-year results

The novel, small-diameter OmniaSecure™ defibrillation lead is projected to be highly durable.

OmniaSecure™ defibrillation lead predicted to be highly durable with an overall 98.2% fracture-free rate at 10 years9
View the data (open in new window)

Specifications

This is an illustration of the OmniaSecure™ defibrillation lead with numbered callouts.
This is an illustration of the OmniaSecure™ defibrillation lead cross section with numbered callouts.

1. 4.7 Fr lead body

2. DF4 connector

3. Fixed helix

4. Steroid-eluting ring

5. Defibrillation coil

6. Integrated bipolar sensing

7. Conductor cable: MP35N

8. Inner insulation: ETFE

9. Inner insulation: silicone

10. Conductor coil: silver cored MP35N

11. Conductor coil insulation: SI polyimide

12. Outer insulation: 55D polyurethane

Implant procedure

Watch to learn more about the OmniaSecure™ lead implant procedure.

Ordering information

Item number Type Fixation Connector MR Conditional length (cm) Diameter (Fr)
3930M64 Single coil, bipolar Helix, active fixation DF4 64 4.7
3930M69 Single coil, bipolar Helix, active fixation DF4 69 4.7
3930M74 Single coil, bipolar Helix, active fixation DF4 74 4.7
3930M79 Single coil, bipolar Helix, active fixation DF4 79 4.7
3930M84 Single coil, bipolar Helix, active fixation DF4 84 4.7

 

Related links

Similar products

  1. SecureD lead cross-sectional area and volume calculations. September 2021. Medtronic data on file.
  2. Bharmanee A, Zelin K, Sanil Y, Gupta P, Karpawich PP. Comparative chronic valve and venous effects of lumenless versus stylet-delivered pacing leads in patients with and without congenital heart. Pacing Clin Electrophysiol. 2015;38(11):1343–1350. doi:10.1111/pace.12728.
  3. Çeliker C, Sayman H, Ersanli M, et al. Diagnosis of abnormal subclavian venous flow by radionuclide venography in patients with permanent pacemaker. Int J Angiol. 1998;7(3):265–267. doi:10.1007/BF01617409.
  4. Tatum R, Maynes EJ, Wood CT, et al. Tricuspid regurgitation associated with implantable electrical device insertion: A systematic review and meta-analysis. Pacing Clin Electrophysiol. 2021;44(8):1297–1302. doi:10.1111/pace.14287.
  5. Crossley GH III, Sanders P, Hansky B, et al. Safety, efficacy, and reliability evaluation ofa novel small-diameter defibrillation lead: Global LEADR pivotal trial results. Heart Rhythm. 2024;21(10):1914–1922. doi:10.1016/j.hrthm.2024.04.067.
  6. Crossley GH, Sanders P, De Filippo P, et al. Rationale and design of the Lead EvaluAtion for Defibrillation and Reliability study: Safety and efficacy of a novel ICD lead design. J Cardiovasc Electrophysiol. 2023;34(2):257–267. doi:10.1111/jce.15747.
  7. Crossley GH, Mason PK, Hansky B, et al. High predicted durability for the novel small-diameter OmniaSecure defibrillation lead. Heart Rhythm. 2025;22(2):302–310. doi:10.1016/j.hrthm.2024.09.005.
  8. Sanders P, Mason PK, Hansky B, et al. Sensing and detection performance of the novel, small-diameter OmniaSecure defibrilla­tion lead: in-depth analysis from the LEADR trial. Europace. 2025:euaf062. doi:10.1093/europace/euaf062.
  9. Crossley GH III, Mason PK, Hansky B, et al. High predicted durability for the novel small-diameter OmniaSecure defibrillation lead. Heart Rhythm. 2025;22(2):302–310. doi:10.1016/j.hrthm.2024.09.005.